Target Price | €44.48 |
Price | €40.16 |
Potential | 10.78% |
Number of Estimates | 18 |
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €44.48. This is 10.78% higher than the current stock price. The highest price target is €51.11 27.29% , the lowest is €38.82 3.34% . | |
A rating was issued by 24 analysts: 12 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 10.78% . Most analysts recommend the Qiagen stock at Buy or hold. |
24 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 4.11% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 8.08% , the lowest is €1.7b 2.21% .
This results in the following potential growth metrics:
2024 | €1.7b | 0.66% |
---|---|---|
2025 | €1.8b | 7.37% |
2026 | €1.9b | 5.70% |
2027 | €2.0b | 6.73% |
2028 | €2.3b | 12.10% |
2029 | €2.5b | 7.26% |
2030 | €2.9b | 16.45% |
22 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €673m . This is 41.77% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €751m 58.16% , the lowest is €600m 26.42% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €431m | 10.65% |
---|---|---|
2025 | €673m | 56.13% |
2026 | €723m | 7.50% |
2027 | €781m | 8.01% |
2028 | €827m | 5.89% |
2029 | €852m | 3.00% |
2024 | 25.51% | 9.92% |
---|---|---|
2025 | 37.09% | 45.42% |
2026 | 37.72% | 1.70% |
2027 | 38.17% | 1.19% |
2028 | 36.06% | 5.53% |
2029 | 34.63% | 3.97% |
25 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €447m . This is 40.15% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €537m 68.29% , the lowest is €420m 31.86% .
This results in the following potential growth metrics and future Net Margins:
2024 | €71.4m | 75.51% |
---|---|---|
2025 | €447m | 526.00% |
2026 | €483m | 8.02% |
2027 | €525m | 8.84% |
2028 | €579m | 10.28% |
2029 | €605m | 4.45% |
2024 | 4.23% | 75.67% |
---|---|---|
2025 | 24.64% | 483.10% |
2026 | 25.18% | 2.19% |
2027 | 25.68% | 1.99% |
2028 | 25.26% | 1.64% |
2029 | 24.60% | 2.61% |
25 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.06 . This is 42.07% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.47 70.34% , the lowest is €1.94 33.79% .
This results in the following potential growth metrics and future valuations:
2024 | €0.33 | 74.81% |
---|---|---|
2025 | €2.06 | 524.24% |
2026 | €2.23 | 8.25% |
2027 | €2.42 | 8.52% |
2028 | €2.67 | 10.33% |
2029 | €2.79 | 4.49% |
Current | 27.68 | 75.41% |
---|---|---|
2025 | 19.47 | 29.65% |
2026 | 18.02 | 7.45% |
2027 | 16.56 | 8.10% |
2028 | 15.02 | 9.30% |
2029 | 14.38 | 4.26% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 5.02 and an P/S ratio of 4.79 .
This results in the following potential growth metrics and future valuations:
Current | 5.23 | 1.69% |
---|---|---|
2025 | 5.02 | 4.04% |
2026 | 4.75 | 5.39% |
2027 | 4.45 | 6.30% |
2028 | 3.97 | 10.80% |
2029 | 3.70 | 6.77% |
2030 | 3.18 | 14.13% |
Current | 4.98 | 2.25% |
---|---|---|
2025 | 4.79 | 3.95% |
2026 | 4.53 | 5.39% |
2027 | 4.24 | 6.30% |
2028 | 3.79 | 10.80% |
2029 | 3.53 | 6.77% |
2030 | 3.03 | 14.13% |
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 02 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 02 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.